The combination of EphA2-ILs-DTXp and gemcitabine led to significantly greater tumor regression than either drug alone (ANOVA and post-hoc Tukey HSD Combination vs. Gem: BL-0293 p < 0.01; BL-0382 p < 0.0001; BL-0440 p < 0.0001; Combination vs. EphA2-ILs-DTXp: BL-0293 p < 0.05; BL-0382 p < 0.0001; BL-0440 p < 0.0001) (Figure 4B). The gene discussed is EPHA2; the disease is neoplasm.